
Project Description
Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment manufactured by Beacon Pharmaceuticals Limited. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).


Project Details
Client: Beacon Pharmaceuticals Limited
Date: 27.07.2016
Skills: Branding, Web Design, Hepatitis C Product’s Website
View: http://www.sofosvel.com

Like What You See?
Years in Business
Companies Served
%
Satisfied Clients
Get In Touch
+880 131 3450 777
Address
Suite: 601, Level: 6,
Concord Tower, 113 Kazi Nazrul Islam Avenue, Dhaka-1000, Bangladesh.
hello@reinforcelab.com
service@reinforcelab.com
support@reinforcelab.com
Open Hours
Saturday – Thursday : 10am – 6pm,
Friday: Closed